Sign inJoin waitlistJoin the waitlist

Louis Nabors

Neuro-Oncology Division and Program Director · University of Alabama Hospital

Credentials: · · ·

History

Neuro-Oncology Division and · University of Alabama Hospital
Present
Neurology and Vice Chair for Research · University of Alabama Hospital
Present
University of Alabama Hospital
Present

University of Alabama at Birmingham
1998–1999
University of Alabama at Birmingham
1994–1998
University of Tennessee College of Medicine
1987–1991
B.S. Engineering Mississippi State University

Research

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre,…
The Lancet Oncology · 2014 · 871 citations
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
New England Journal of Medicine · 2023 · 643 citations
Human cytomegalovirus infection and expression in human malignant glioma
Cancer Research · 2002 · 575 citations

PW
Patrick Wen
35 papers
SG
Stuart Grossman
35 papers
David Reardon
25 papers
Peter King
25 papers
John Fiveash
23 papers
Roger Stupp
23 papers
Jeffrey Olson
22 papers
James Markert
21 papers
Tom Mikkelsen
21 papers
Reid Thompson
20 papers
MH
Matthias Holdhoff
17 papers
Timothy Cloughesy
15 papers

Grants

ELAVL1 Role in Glioblastoma Heterogeneity Through Intercellular Gene Transfer Mediated by Cell Fusion and Tunneling Membrane Nanotube Formation
National Cancer Institute · R01
Contact PI · $1.3M · University of Alabama at Birmingham
2023–2028
Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.3M · University of Alabama at Birmingham
1997–2027
Network of Excellence in Neuroscience Clinical Trials (NEXT)
National Institute of Neurological Disorders and Stroke · U24
Contact PI · $1.5M · University of Alabama at Birmingham
2018–2024
Cytoplasmic Multimerization of the RNA-Binding Protein HuR Is Oncogenic in Glioma
National Cancer Institute · R01
Contact PI · $1.5M · University of Alabama at Birmingham
2015–2021

Clinical trials

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
In8bio Inc.
2023–2025
Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
Principal investigator · Active not recruiting · Phase 1
University of Alabama at Birmingham
2020–2026
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Principal investigator · Terminated · Phase 2
Cortice Biosciences, Inc.
2014–2015
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Principal investigator · Suspended · Phase 1, Phase 2
Cortice Biosciences, Inc.
2013–2025